1 / 6

Plaque Psoriasis Therapeutic Assessment Pipeline Review H1 2015

This report gives extensive data on the restorative improvement for Plaque (Psoriasis Vulgaris), complete with similar examination at different stages, therapeutics evaluation by medication target, instrument of activity (MoA), course of organization (RoA) and particle sort, alongside most recent overhauls, and included news and press discharges. It additionally audits key players included in the helpful improvement for Plaque (Psoriasis Vulgaris) and exceptional elements on late-stage and suspended undertakings.

RamonEMarshall01
Download Presentation

Plaque Psoriasis Therapeutic Assessment Pipeline Review H1 2015

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2015 By RnRMarketResearch.com Publisher Name : Global Market Direct Date: 29-May-2015 No. of pages: 235 Single User License: US $2000 Browse more Reports on Dermatology Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/dermatology-therapeutics . ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  2. Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2015 This report gives extensive data on the restorative improvement for Plaque (Psoriasis Vulgaris), complete with similar examination at different stages, therapeutics evaluation by medication target, instrument of activity (MoA), course of organization (RoA) and particle sort, alongside most recent overhauls, and included news and press discharges. It additionally audits key players included in the helpful improvement for Plaque (Psoriasis Vulgaris) and exceptional elements on late-stage and suspended undertakings. The report upgrades choice making capacities and help to make powerful counter methods to increase game changer. It fortifies R&D pipelines by distinguishing new targets and MOAs to deliver first-in-class and best-in-class items. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  3. Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2015 Companies Discussed/Mentioned in this Research : Almirall, S.A., Amgen Inc., Avesthagen Limited, Avexxin AS, Biocon Limited, Biotie Therapies Corp., Can-FiteBioPharma Ltd., Celltrion, Inc., Circassia Pharmaceuticals plc, CoherusBioSciences, Inc., Creabilis SA, Delenex Therapeutics AG, Dermira Inc., Epirus Biopharmaceuticals, Inc., Forward Pharma A/S, Galectin Therapeutics, Inc., GenorBioPharma Co., Ltd., Idera Pharmaceuticals, Inc., and more.. Drugs Profile Discussed in this Research : (betamethasone dipropionate + bexarotene), (calcipotriene + betamethasone dipropionate), (calcipotriene + betamethasone), adalimumab biosimilar, AM-001,ASKP-1240, AVX-001, betamethasone + maxacalcitol, bimekizumab, brodalumab, BTT-1023, calcipotriene, CF-101, CIR-001, CT-327, dalazatide, DFD-01, DFD-06, dimethyl fumarate, DLX-105, DRM-02, etanerceptbiosimilarand more.. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  4. Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2015 Scope For Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2015 • The report provides a snapshot of the global therapeutic landscape of Plaque Psoriasis (Psoriasis Vulgaris) • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities • The report reviews key players involved in the therapeutics development for Plaque Psoriasis (Psoriasis Vulgaris) and enlists all their major and minor projects • The report summarizes all the dormant and discontinued pipeline projects • A review of the Plaque Psoriasis (Psoriasis Vulgaris) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  5. Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2015 Reasons to Buy: • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • Develop strategic initiatives by understanding the focus areas of leading companies • Identify and understand important and diverse types of therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris) • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline • Devise corrective measures for pipeline projects by understanding Plaque Psoriasis (Psoriasis Vulgaris) pipeline depth and focus of Indication therapeutics ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  6. Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2015 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

More Related